Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00324389 · ClinicalTrials.gov registry record · Phase 2
Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00324389 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2 participants.
The verdict
NCT00324389, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This proposal seeks to use DNA analyses to understand how racial and genetic factors influence interferon (treatment) response in HCV infection in African Americans. A better understanding should allow rational design of new therapies or better use of existing therapies. Patients will provide medical history and undergo a physical exam, blood draws, electrocardiogram, possible chest x-ray, and abdominal ultrasound. Patients will be admitted to the hospital for 5 days and undergo 2 liver biopsies, sedation, and multiple blood draws. Twenty adult male volunteers (10 Caucasians,10 African Americans) ages 18 - 65 years will participate.
Interventions
- DRUG Interferon alpha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00324389
The ClinicalTrials.gov registry entry for NCT00324389 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon alpha is the first listed.
NCT00324389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00324389 about?
NCT00324389 is a clinical study titled "Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes". This proposal seeks to use DNA analyses to understand how racial and genetic factors influence interferon (treatment) response in HCV infection in African Americans. A better understanding should allow rational design of new therapies or better use of existing therapies. Patients will provide medica...
What is the current status of trial NCT00324389?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2006-05. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00324389?
The interventions under investigation include: Interferon alpha (DRUG).
Who is sponsoring clinical trial NCT00324389?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.